Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: PAVmed is a multi-product life sciences company structured as a parent holding company with distinct subsidiaries for specific assets. Key subsidiaries include Lucid Diagnostics (LUCD), focused on the EsoGuard esophageal cancer screening test, and Veris Health, focused on the Veris Cancer Care Platform. The company also operates an incubator program (PMX) for other technologies.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $3.0 million | $2.5 million |
| Operating Loss | $(44.5) million | $(68.8) million |
| Net Income (Loss) Attributable to PAVmed | $39.8 million | $(64.2) million |
| Net Income (Loss) Attributable to Common Stockholders | $32.0 million | $(66.3) million |
| Cash and Cash Equivalents (End of Period) | $1.2 million | $19.6 million |
| Net Cash Used in Operating Activities | $(33.6) million | $(52.0) million |
| Total Debt (Senior Secured Convertible Notes at Fair Value) | $29.1 million | $44.2 million |
Note: The 2024 Net Income is significantly influenced by a non-cash gain on the deconsolidation of Lucid Diagnostics.
Material Changes vs. Prior Period
- Deconsolidation of Lucid Diagnostics: On September 10, 2024, PAVmed lost control of its subsidiary Lucid Diagnostics due to changes in board composition and voting rights. Lucid was deconsolidated from PAVmed's financial statements. This resulted in a $72.3 million non-cash gain on deconsolidation, which drove the reported net income for 2024 despite ongoing operational losses.
- Revenue Growth: Revenue increased by $0.5 million (20%) to $3.0 million, primarily driven by EsoGuard test results delivered prior to deconsolidation.
- Expense Reduction: Total operating expenses decreased by $23.8 million to $47.5 million. This reduction is largely attributable to the deconsolidation of Lucid, which removed its sales, marketing, and R&D costs from PAVmed's consolidated results for the latter part of the year.
- Debt Restructuring: The company engaged in significant debt management activities, including the exchange of $22.3 million of convertible notes for Series C Preferred Stock (consummated in January 2025) and the repayment of Lucid's 2023 convertible note.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
The independent registered public accounting firm has issued an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern. This is due to recurring operating losses, negative cash flows from operations, and the need to raise additional capital to fund operations beyond March 2026. The company ended 2024 with only $1.2 million in cash.
Recent Financing and Capital Raises
- PAVmed/Veris Offering (Feb 2025): Raised $2.37 million through the sale of common stock and pre-funded warrants to fund Veris development.
- Lucid Offering (Mar 2025): Lucid Diagnostics raised approximately $14.5 million net in a registered direct offering.
- Debt Exchange (Jan 2025): Exchanged $22.3 million of senior secured convertible notes for Series C Preferred Stock to improve stockholders' equity and regain Nasdaq compliance.
Nasdaq Compliance
The company regained compliance with Nasdaq stockholders' equity requirements ($2.5 million) in February 2025. However, it received a notice in January 2025 regarding non-compliance with the minimum bid price requirement ($1.00). The company has 180 days (until July 22, 2025) to regain compliance or face delisting.
Key Risks
- Reimbursement Uncertainty: While EsoGuard has a Medicare payment determination, a Local Coverage Determination (LCD) currently indicates non-coverage pending further evidence. PAVmed submitted a request for reconsideration in November 2024.
- Liquidity: Heavy reliance on subsidiaries (Lucid, Veris) to raise capital to fund parent company operations.
- Regulatory: FDA phase-out of enforcement discretion for Laboratory Developed Tests (LDTs) requires compliance with quality system regulations by 2025-2028.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.2 million cash balance on hand against the company's burn rate and the timeline for the next capital raise.
- Lucid Deconsolidation Impact: Confirm that the $72.3 million gain is non-cash and does not reflect operational profitability; review the equity method accounting for the remaining Lucid stake.
- Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before July 22, 2025.
- Medicare Coverage Status: Track the outcome of the request for reconsideration of the Local Coverage Determination (LCD) for EsoGuard, as this is critical for commercial scale.
- Debt Covenants: Review the terms of the remaining September 2022 Senior Convertible Note and the new Series C Preferred Stock for restrictive covenants and conversion triggers.